Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease

Atherosclerosis

Volumn 144, Issue 1, 1999, Pages 177-184

  Schaefer, J R ^a   Schweer, H ^b   Ikewaki, K ^c   Stracke, H ^a   Seyberth, H J ^b   Kaffarnik, H ^a   Maisch, B ^a   Steinmetz, A ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ApoA I metabolism; In vivo kinetics; Pravastatin; Stable isotope

Indexed keywords

APOLIPOPROTEIN A1; DEUTERIUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; KINETICS; LIPID METABOLISM; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEIN A-I; CORONARY DISEASE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MALE; PRAVASTATIN; REFERENCE VALUES; SOFTWARE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0033049802     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00053-2     Document Type: Article

References (63)

1. Jakob BG, Möhrle W, Richter WP, Schwandt P. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia. Eur J Clin Pharmacol 1992;43:353-8.
2. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993;71:810-815.
3. The European Study Group. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia. Am J Cardiol 1992;70:1281-1286.
4. The Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. J Am Med Assoc 1986;256:2829-2834.
5. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993;71: 1408-1414.
6. Reihner E, Rudling M, Stahlberg D, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990;323:224-8.
7. Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischemic heart disease. Lancet 1975;l:16-9.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
10. Tonkin A. Long term Intervention with pravastatin in ischemic disease (LIPID). AHA Abstract book 1997; 70th Congress of AHA:629 (Abstract).
11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
12. Kuivenhoven JA, Wouter Jukema J, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998;338:86-93.
13. Vega GL, East C, Grundy SM. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis 1988;70:131-43.
14. Bagdade JD, Subbaiah PV. Abnormal high-density lipoprotein composition in women with insulin-dependent diabetes. J Lab Clin Med 1989;113:235-40.
15. Vega GL, Grundy SM. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Intern Med 1991;230:341-50.
16. Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990;227:81-94.
17. Watts GF, Cummings MH, Umpleby M, et al. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 1995;25:559-67.
18. Aguilar Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G. Physiologic mechanisms of action of lovastatin in nephrotic syndrome. J Lipid Res 1995;36:188-99.
19. Schaefer JR, Rader DJ, Brewer HBJ. Investigation of lipoprotein kinetics using endogenous labelling with stable isotopes. Curr Opin Lipidol 1992;3:227-32.
20. Watson TD. New in vivo techniques for measuring lipoprotein metabolism. Curr Opin Lipidol 1995;6:182-6.
21. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HBJ. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 1993;34:2207-15.
22. Schaefer JR, Rader DJ, Gregg RE, et al. In vivo protein metabolism utilizing stable isotopes and mass spectrometry: a new approach to the study of mutant proteins in humans. Trans Assoc Am Phys 1990;103:187-94.
23. Schaefer JR, Rader DJ, Ikewaki K, et al. In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. Arterioscler Thromb 1992;12:843-8.
24. Schaefer JR, Scharnagl H, Baumstark MW, et al. Homozygous familial defective apolipoprotein B-100: enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb Vase Biol 1997;17:348-53.
25. Wolfe RR. Tracers in Metabolie Research. Radioisotope and Stable Isotope-Mass Spectrometry Methods. New York: A.R. Liss, 1984:1-274.
26. MacKenzie SL, Tenaschuk D. Gas-liquid chromatography of N-heptafluorobutyryl isobutyl esters of amino acids. J Chromatogr 1974;97:19-24.
27. Schweer H, Watzer B, Seyberth HJ, Steinmetz A, Schaefer JR. Determination of isotopic ratios of L-leucine and L-phenylalanine and their labelled analogues in plasma by gas chromatography-triple stage quadrupole mass spectrometry. J Mass Spectrom 1996;31:727-34.
28. Cobelli C, Toffolo G, Foster DM. Tracer to tracee ratio for analysis of stable isotope tracer data: link with radioactive formalism. Am J Physiol 1992;262:E968-75.
29. Havel RJ, Eder H, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-50.
30. Meng MS, Gregg RE, Schaefer EJ, Hoeg JM, Brewer HBJ. Presence of two isoforms of apolipoprotein B in patients with dysbetalipoproteinemia. J Lipid Res 1983;24:803-9.
31. Steinmetz A, Jakobs C, Motzny S, Kaffarnik H. Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis 1989;9:405-11.
32. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11:583-95.
33. Hackler R, Schaefer JR, Motzny S, et al. Rapid determination of apolipoprotein E phenotypes from whole plasma by automated isoelectric focusing using PhastSystem and immunofixation. J Lipid Res 1994;35:153-8.
34. Schaefer JR, Hackler R, Brand S, Schwarz S, Kleine TO, Steinmetz A. Apolipoprotein AI, AII, and AIV isoforms in plasma determined by automated isoelectric focusing with PhastSystem and immunofixation. Clin Chem 1995;41:76-81.
35. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apoA-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 1990;85:804-11.
36. Lichtenstein AH, Cohn JS, Hachey DL, Millar JS, Ordovas JM, Schaefer EJ. Comparison of deuterated leucine, valine, and lysine in the measurement of human apolipoprotein A-I and B-100 kinetics. J Lipid Res 1990;31:1693-701.
37. Cryer DR, Matsushima T, Marsh JB, Yudkoff M, Coates PM, Cortner JA. Direct measurement of apolipoprotein B synthesis in human very low density lipoprotein using stable isotopes and mass spectrometry. J Lipid Res 1986;27:508-16.
38. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
39. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: Framingham study. Am J Med 1977;62:707-11.
40. Naito HK. The association of serum lipids, lipoproteins, and apolipoproteins with coronary artery disease assessed by coronary arteriography. Ann NY Acad Sei 1985;454:230-8.
41. Naito HK, Greenstreet RL, David JA, et al. HDL-cholesterol concentration and severity of coronary atherosclerosis determined by cine-angiography. Artery 1980;8:101-12.
42. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med 1989;321:1311-6.
43. Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996;7:209-16.
44. Streja D, Steiner G, Kwiterovich POJ. Plasma high-density lipoproteins and ischemic heart disease: studies in a large kindred with familial hypercholesterolemia. Ann Intern Med 1978;89:871-80.
45. Paigen B, Mitchell D, Reue K, Morrow A, Lusis AJ, LeBoeuf RC. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc Natl Acad Sei USA 1987;84:3763-7.
46. Yoshino G, Iwai M, Kazumi T, et al. Cholesterol-enrichment of low density lipoprotein fraction is absent in Japanese normolipidemic diabetics. Horm Metab Res 1989;21:152-3.
47. Nishina PM, Wang J, Toyofuku W, Kuypers FA, Ishida BY, Paigen B. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids 1993;28:599-605.
48. Saku K, Yamamoto K, Sakai T, et al. Kinetics of HDL-apo A-I in the WHHL rabbit, an animal model of familial hypercholesterolemia. Atherosclerosis 1989;79:225-30.
49. Saku K, Harada R, Yamamoto K, Ying H, Ozaki I, Arakawa K. Apolipoprotein AI mRNA levels in WHHL rabbits. Atherosclerosis 1990;84:73-4 Letter.
50. Rader DJ, Ikewaki K, Duverger N, et al. Very low high-density lipoproteins without coronary atherosclerosis. Lancet 1993;342:1455-8.
51. Hirano K, Yamashita S, Kuga Y, et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vase Biol 1995; 15:1849-56.
52. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917-23.
53. Ikewaki K, Rader DJ, Sakamoto T, et al. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993;92:1650-8.
54. Schaefer JR, Steinmetz A, Schweer H, et al. Different in vivo mechanisms leading to a decrease in LDL cholesterol and apolipoprotein B-100 in subjects treated with HMG-CoA reductase inhibitor. In: Jaross W, Hanefeld M, Bergmann S, Dude H, editors. Advances in Lipoprotein and Atherosclerosis Research, Diagnostics and Treatment. New York: Gustav Fischer, 1995:262-7.
55. Schwartz CC, Zech LA, Vandenbroek JM, Cooper PS. Reverse cholesterol transport measured in vivo in man: the central roles of HDL. In: Miller NE, editor. High Density Lipoproteins and Atherosclerosis. Amsterdam: Excerpta Medica, 1989:321-9.
56. Francis GA, Ko K, Hara H, Yokoyama S. Regulation of high density lipoprotein originated cholesteryl ester by HepG2 cells: role of low density lipoprotein and plasma lipid transfer protein. Biochim Biophys Acta 1991;1084:159-66.
57. Fisher WR, Zech LA, Stacpoole PW. ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm. Arterioscler Thromb 1994;14:501-10.
58. Ginsberg HN, Ngai C, Ramakrishnan R. Lovastatin increases apolipoprotein A-I levels in subjects with isolated reductions in high density lipoproteins. Circulation 1991;84:II-140 Abstract.
59. Mitchell A, Fidge N, Griffiths P. The effect of the HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat. Biochim Biophys Acta 1993;1167:9-14.
60. Monge JC, Hoeg JM, Law SW, Brewer HBJ. Effect of low density lipoproteins, high density lipoproteins, and cholesterol on apolipoprotein A-I mRNA in Hep G2 cells. FEES Lett 1989;243:213-7.
61. Rader DJ, Schaefer JR, Lohse P, et al. Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism 1993;42:1429-34.
62. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265-7.
63. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993;365:762-4.